Crossmark

A Single-Center Experience with Dupilumab for Atopic or Psoriasiform Dermatitis in Patients with Inflammatory Bowel Disease

Published Online: 2022-09-05

Published Print: 2023-04

Authors

Spencer, Elizabeth A. https://orcid.org/0000-0002-6787-1164
Dolinger, Michael T.

Dubinsky, Marla C.
License Information

Text and Data Mining valid from 2022-09-05

Version of Record valid from 2022-09-05
More Information

Article History

Received: 20 July 2022

Accepted: 23 August 2022

First Online: 5 September 2022

Declarations

:

: EAS received consulting fees from Prometheus Biosciences. Dr. Spencer is supported on a NIH grant. MTD received consulting fees from Neurologica Corp., a subsidiary of Samsung Electronics Co., Ltd. MCD received consulting fees from Abbvie, Amgen, Arena Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Celgene, Ferring, Genentech, Gilead, Hoffmann-La Roche, Janssen, Pfizer, Prometheus Biosciences, Takeda, and Target PharmaSolutions; research funding from Abbvie, Janssen, Pfizer, Prometheus Biosciences, and Takeda; and is a Co-founder for Trellus Health.

Document is current